[1]徐凯,潘俊综述,毛立军*审校. 溶瘤腺病毒治疗实体肿瘤研究进展[J].徐州医科大学学报,2017,37(05):343-346.
 [J].Journal of Xuzhou Medical University,2017,37(05):343-346.
点击复制

 溶瘤腺病毒治疗实体肿瘤研究进展()
分享到:

《徐州医科大学学报》[ISSN:2096-3882/CN:32-1875/R]

卷:
37
期数:
2017年05期
页码:
343-346
栏目:
出版日期:
2017-05-25

文章信息/Info

作者:
 徐凯潘俊综述毛立军*审校
徐州医科大学附属医院泌尿外科,江苏徐州221002
关键词:
 溶瘤腺病毒肿瘤基因治疗
分类号:
R370.5
文献标志码:
A
摘要:
 溶瘤腺病毒能选择性地在肿瘤细胞内增殖,裂解肿瘤细胞,而对邻近正常细胞几乎无影响,是肿瘤基因治疗的理想载体。通过基因工程改造,溶瘤腺病毒能感染特定类型肿瘤细胞,发挥抗肿瘤效果。然而,实体肿瘤复杂的组织学结构和免疫逃避机制明显限制溶瘤腺病毒的溶瘤效果,无法将肿瘤彻底根除。荷载表达相关结构分子、免疫调节分子的溶瘤腺病毒能靶向肿瘤微环境及提高肿瘤免疫,提高抗肿瘤效果,为溶瘤腺病毒介导的癌症基因疗法提供新平台。

参考文献/References:

[1]Choi JW, Lee YS, Yun CO,et al. Polymeric oncolytic adenovirus for cancer gene therapy [J]. J Control Release, 2015,219:181-191.
[2]Andtbacka RH, Kaufman HL, Collichio F,et al. Talimogene laherparepvec improves durable response rate in patients with advanced Mmelanoma [J]. J Clin Oncol, 2015,33(25):2780-2788.
[3]Shen YH, Yang F, Wang H,et al. Arg-Gly-Asp (RGD)-modified E1A/E1B double mutant adenovirus enhances antitumor activity in prostate cancer cells in vitro and in mice [J/OL]. PLoS One, 2016,11(1):e0147173.
[4]Bauerschmitz GJ, Lam JT, Kanerva A,et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus [J]. Cancer Res, 2002,62(5):1266-1270.
[5]Wang H, Li ZY, Liu Y,  et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14 [J]. Nat Med, 2011,17(1):96-104.
[6]Rojas JJ, Guedan S, Searle PF, et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses [J]. Mol Ther, 2010,18(11):1960-1971.
[7]Sarkar S, Quinn BA, Shen XN, et al. Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3mimetic [J]. Oncotarget,   2015,6(13):10712-10727.
[8]Lee SY, Park HR, Rhee J, et al. Therapeutic effect of oncolytic adenovirus expressing relaxin in radioresistant oral squamous cell carcinoma [J]. Oncol Res, 2013,20(9):419-425.
[9]Guedan S, Rojas JJ, Gros A,et al. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth [J]. Mol Ther, 2010,18(7):1275-1283.
[10]Vera B, Martínez-Vélez N, Xipell E,et al. Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01 [J/OL]. PLoS One, 2016,11(1):e0147211.
[11]Lucas T, Benihoud K, Vigant F, et al. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplasticand stromal cells in pancreatic cancer [J/OL]. PLoS One, 2015,10(2):e0117254.
[12]Thaci B, Ulasov IV, Ahmed AU, et al. Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagendegradation [J]. Gene Ther, 2013,20(3):318-327.
[13]Choi IK, Shin H, Oh E, et al. Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus [J]. Int J Cancer, 2015,137(9):2253-2269.
[14]Li LX, Zhang YL, Zhou L,et al. Antitumor efficacy ofa recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells [J]. J Transl Med, 2013,11:257.
[15]Loskog A. Immunostimulatory gene therapy using oncolytic viruses as vehicles [J]. Viruses, 2015,7(11):5780-5791.
[16]Ostuni R, Kratochvill F, Murray PJ,et al. Macrophages and cancer: from mechanisms to therapeutic implications [J]. Trends Immunol, 2015,36(4):229-239.
[17]Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients witha serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF [J]. Mol Ther, 2010,18(10):1874-1884.
[18]Ranki T, Pesonen S, Hemminki A,et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinicalresponse and exploratory analyses of immune markers [J]. J Immunother Cancer, 2016,4:17.
[19]Vassilev L, Ranki T, Joensuu T,et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cellresponse and robust cellular and transcriptional immune activation at tumor site in a patient withovarian cancer [J/OL]. Oncoimmunology, 2015,4(7):e1017702.
[20]Hirvinen M, Rajecki M, Kapanen M,et al. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus [J]. Hum Gene Ther, 2015,26(3):134-144.
[21]Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinicalmodel of prostate cancer [J]. Gene Ther, 2013,20(12):1131-1139.
[22]He B, Huang X, Liu X,et al. Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24in immune-competent mice [J]. Mol Biol Rep, 2013,40(9):5397-5405.
[23]Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients [J]. Cancer Res, 2012,72(7):1621-1631.
[24]Farzad L, Cerullo V, Yagyu S,  et al. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy [J]. Mol Ther Oncolytics, 2014,1:14008.

相似文献/References:

[1]孙秀媛,李海玲,朱相华,等.rTMS及MECT在不同时间点对抑郁症疗效和BDNF的影响及相关性研究[J].徐州医科大学学报,2017,37(04):262.
[2]代春潇,宋远见,张云山,等. 大鼠MKK7真核表达质粒的构建及其在COS7细胞中转染效率[J].徐州医科大学学报,2017,37(04):211.
  [J].Journal of Xuzhou Medical University,2017,37(05):211.
[3]张端强,丁晓帆,杨丹丹,等. 加综合征患者复发影响因素研究[J].徐州医科大学学报,2017,37(04):216.
 [J].Journal of Xuzhou Medical University,2017,37(05):216.
[4]王立新,袁峰*,郭开今,等. 纳米羟基磷灰石/细菌纤维素对兔骨髓间充质干细胞黏附及成骨分化的影响[J].徐州医科大学学报,2017,37(04):221.
 [J].Journal of Xuzhou Medical University,2017,37(05):221.
[5]李海青,曹猛,江涛,等. PD-L1在结直肠癌中的表达及其临床意义[J].徐州医科大学学报,2017,37(04):227.
 [J].Journal of Xuzhou Medical University,2017,37(05):227.
[6]刘兵,唐明生,李苹,等. 用随机森林模型分析胃癌高危人群干预效果的影响因素*[J].徐州医科大学学报,2017,37(04):231.
 [J].Journal of Xuzhou Medical University,2017,37(05):231.
[7]周新宇?,牛坚,曹宽,等. Tim3在炎症反应调控及对肝细胞损伤保护机制研究[J].徐州医科大学学报,2017,37(04):236.
 [J].Journal of Xuzhou Medical University,2017,37(05):236.
[8]商书霞,宋光耀*,刘晓耕,等. 血清胆红素和γ-谷氨酰转肽酶与糖尿病患者非酒精性脂肪肝的相关性研究[J].徐州医科大学学报,2017,37(04):245.
 [J].Journal of Xuzhou Medical University,2017,37(05):245.
[9]李新文1,巩尊科2,王世雁2,等. RS在非痴呆型血管性认知障碍评定中的临床应用研究[J].徐州医科大学学报,2017,37(04):248.
 [J].Journal of Xuzhou Medical University,2017,37(05):248.
[10]樊叶,韩维维,何帮顺,等.替格瑞洛含药血清对人胃黏膜上皮细胞GES-1的损伤作用[J].徐州医科大学学报,2017,37(04):252.
 [J].Journal of Xuzhou Medical University,2017,37(05):252.

备注/Memo

备注/Memo:
 基金项目:江苏省自然科学基金(BK20151166)
*通信作者,E-mail:mljmlj05@126.com
更新日期/Last Update: 2017-06-09